^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

    Published date:
    11/16/2020
    Excerpt:
    JAVELIN Gastric 100 did not demonstrate superior OS with avelumab maintenance versus continued chemotherapy in patients with advanced GC or GEJC overall or in a prespecified PD-L1–positive population.
    DOI:
    10.1200/JCO.20.00892
    Trial ID:
    JAVELIN Gastric 100